Blerina Resuli: Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated NSCLC
Blerina Resuli, Consultant Clinical Oncologist in Thoracic Oncology at LMU University Hospital Munich, posted on LinkedIn
“Exploratory ADAURA analysis highlights the potential of plasma-based, tumour-informed MRD to predict recurrence during and after adjuvant osimertinib in resected EGFR-mutant NSCLC.
MRD detection preceded radiographic recurrence by a median of 4.7 months and may help identify patients at risk of relapse, particularly after completing 3 years of adjuvant therapy. These findings support the integration of ctDNA-based MRD as a dynamic biomarker to guide surveillance and potentially personalize treatment duration.
Prospective validation will be key to translating this into clinical practice.”
Authors: Roy S. Herbst, Thomas John, Christian Grohé, Jonathan W. Goldman, Terufumi Kato, Konstantin Laktionov, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung-Ju Ahn, Dariusz M. Kowalski, Maurice Pérol, Virote Sriuranpong, Mustafa Özgüroğlu, Preetida Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, Caitlin Muldoon, Jacqulyne Robichaux, Ryan Hartmaier, Masahiro Tsuboi and Yi-Long Wu
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023